gross profit bridgeinconsistent2020-09-30
Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.
Revenue
$21.84B
Fiscal year ended 2025-09-30Operating income
$2.58B
Fiscal year ended 2025-09-30Free cash flow
Unavailable
Fiscal year ended 2025-09-30BECTON DICKINSON & CO (BDX) reported revenue of $21.84B and net income of $1.68B for the fiscal year ended 2025-09-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BECTON DICKINSON & CO’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.
Income
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 | 2017-09-30 | 2016-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.84B | $20.18B | $19.37B | $18.87B | $19.13B | $16.07B | $17.29B | $15.98B | $12.09B | $12.48B |
| Cost of revenue | $11.92B | $11.05B | $11.20B | $10.39B | $10.50B | Unavailable | $9.00B | $8.71B | $6.13B | $6.49B |
| Gross profit | $9.92B | $9.12B | $8.17B | $8.48B | $8.63B | Unavailable | $8.29B | $7.27B | $5.94B | $5.99B |
| Operating income | $2.58B | $2.40B | $2.11B | $2.28B | $2.25B | $912.00M | $1.76B | $1.51B | $1.52B | $1.43B |
| Net income | $1.68B | $1.70B | $1.48B | $1.78B | $2.09B | $874.00M | $1.23B | $311.00M | $1.10B | $976.00M |
| Research & development | $1.26B | $1.19B | $1.24B | $1.26B | $1.28B | $1.04B | $1.06B | $1.00B | $770.00M | $828.00M |
| Weighted-average diluted shares | shares 288.51M | shares 291.01M | shares 288.39M | shares 287.36M | shares 292.09M | shares 282.40M | shares 274.78M | shares 264.62M | shares 223.59M | shares 217.54M |
| Pretax income | $1.88B | $2.00B | $1.66B | $1.78B | $1.69B | $414.00M | $1.18B | $1.17B | $976.00M | $1.07B |
| Income tax expense | $203.00M | $300.00M | $132.00M | $148.00M | $88.00M | $62.00M | -$57.00M | $862.00M | -$124.00M | $97.00M |
| Diluted EPS | $5.82 | $5.86 | $4.94 | $5.88 | $6.85 | $2.71 | $3.94 | $0.60 | $4.60 | $4.49 |
| Selling, general & administrative | $5.28B | $4.86B | $4.72B | $4.71B | $4.72B | $4.18B | $4.33B | $4.02B | $2.91B | $3.00B |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 | 2017-09-30 | 2016-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $567.00M | $1.72B | $1.42B | $1.01B | $2.28B | $2.82B | $536.00M | $1.14B | $14.18B | $1.54B |
| Total assets | $55.32B | $57.29B | $52.78B | $52.93B | $53.87B | $54.01B | $51.76B | $53.90B | $37.73B | $25.59B |
| Current assets | $9.26B | $10.47B | $8.68B | $8.14B | $8.84B | $8.97B | $6.66B | $7.41B | $18.63B | $6.37B |
| Total liabilities | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Current liabilities | $8.31B | $8.96B | $6.64B | $7.81B | $6.63B | $5.84B | $5.66B | $7.22B | $3.34B | $4.40B |
| Total equity incl. NCI | $25.39B | $25.89B | $25.80B | $25.28B | $23.68B | $23.76B | $21.08B | $20.99B | $12.95B | $7.63B |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $3.15B | $3.84B | $3.27B | $3.22B | $2.74B | $2.74B | $2.58B | $2.45B | $1.82B | $1.72B |
| Accounts receivable | $2.40B | $3.03B | $2.53B | $2.19B | $2.35B | $2.40B | $2.34B | $2.32B | $1.74B | $1.62B |
| Goodwill | $25.96B | $26.46B | $24.52B | $24.62B | $23.89B | $23.60B | $23.38B | $23.60B | $7.56B | $7.42B |
| Long-term debt | $17.62B | $17.94B | $14.74B | $13.89B | $17.11B | $17.22B | $18.08B | $18.89B | $18.67B | $10.55B |
| Accounts payable | $1.97B | $1.90B | $1.64B | $1.70B | $1.74B | $1.36B | $1.09B | $1.11B | $797.00M | $665.00M |
Cash flow
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 | 2017-09-30 | 2016-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | Unavailable | Unavailable | Unavailable | Unavailable | $4.65B | $3.54B | $3.33B | $2.86B | $2.55B | $2.56B |
| Capital expenditures | $760.00M | $725.00M | $874.00M | $973.00M | $1.19B | $769.00M | $957.00M | $895.00M | $727.00M | $693.00M |
| Investing cash flow | -$818.00M | -$5.51B | -$716.00M | Unavailable | -$1.88B | -$1.23B | -$741.00M | -$15.73B | -$883.00M | -$669.00M |
| Financing cash flow | -$3.62B | $2.09B | -$1.96B | Unavailable | -$3.31B | $22.00M | -$3.22B | -$58.00M | $10.98B | -$1.76B |
| Net change in cash | -$1.00B | $375.00M | $322.00M | -$1.23B | -$525.00M | $2.33B | -$646.00M | -$12.94B | $12.64B | $117.00M |
| Stock-based compensation | $258.00M | $247.00M | $259.00M | $233.00M | $229.00M | $236.00M | $261.00M | $322.00M | $174.00M | $196.00M |
| Common dividends paid | $1.20B | $1.10B | $1.11B | $1.08B | $1.05B | $1.03B | $984.00M | $927.00M | $677.00M | $562.00M |
| Common share repurchases | $1.00B | $500.00M | $0 | $500.00M | $1.75B | $0 | $0 | $0 | $220.00M | $0 |
| Depreciation & amortization | $2.46B | $2.29B | $2.29B | $2.23B | $2.23B | $2.12B | $2.25B | $1.98B | $1.09B | $1.11B |
Derived
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 | 2017-09-30 | 2016-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | $2.37B | $1.97B | $1.82B | $1.87B |
| Gross margin | 45.4% | 45.2% | 42.2% | 44.9% | 45.1% | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating margin | 11.8% | 11.9% | 10.9% | 12.1% | 11.8% | 5.7% | 10.2% | 9.4% | 12.6% | 11.5% |
| FCF margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | 13.7% | 12.3% | 15.1% | 14.9% |
| SBC / revenue | 1.2% | 1.2% | 1.3% | 1.2% | 1.2% | 1.5% | 1.5% | 2.0% | 1.4% | 1.6% |
| Current ratio | 1.11x | 1.17x | 1.31x | 1.04x | 1.33x | 1.54x | 1.18x | 1.03x | 5.58x | 1.45x |
| Revenue YoY growth | 8.2% | 4.2% | 2.7% | -1.4% | 19.0% | -7.0% | 8.2% | 32.2% | -3.1% | Unavailable |
| Net margin | 7.7% | 8.4% | 7.7% | 9.4% | 10.9% | 5.4% | 7.1% | 1.9% | 9.1% | 7.8% |
| R&D / revenue | 5.8% | 5.9% | 6.4% | 6.7% | 6.7% | 6.5% | 6.1% | 6.3% | 6.4% | 6.6% |
| CapEx / revenue | 3.5% | 3.6% | 4.5% | 5.2% | 6.2% | 4.8% | 5.5% | 5.6% | 6.0% | 5.6% |
| Long-term debt / equity | 0.69x | 0.69x | 0.57x | 0.55x | 0.72x | 0.72x | 0.86x | 0.90x | 1.44x | 1.38x |
| Effective tax rate | 10.8% | 15.0% | 7.9% | 8.3% | 5.2% | 15.0% | -4.8% | 73.5% | -12.7% | 9.0% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BDX in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-Q · Filed 2026-02-09View SEC filing
10-K · Filed 2025-11-25View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-01View SEC filing
Reconciliation checks needing review
1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.